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1. Introduction 
Selective Estrogen Receptor Modulators (SERMs) are synthetic compounds originally 
designed as oral contraceptives in the 1960s. During the ensuing decades, they have been 
shown to be effective for the prevention of both invasive and in situ breast cancer, for the 
treatment and prevention of osteoporosis, and for the primary prevention of breast cancer. 
This chapter will review the most important agents focusing on their uterine effect derived 
from dozens of clinical trials that have explored their efficacy for the listed indications. We 
will compare and contrast the agents and highlight recent development of newer, more 
efficacious SERMs that have an improved safety profile.  
2. Tamoxifen 
The finding of a decrease in contralateral breast cancer incidence following tamoxifen 
administration for adjuvant therapy led to the concept that the drug might play a role in 
breast cancer prevention. To test this hypothesis, the National Surgical Adjuvant Breast and 
Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992. Women at increased 
risk for breast cancer were randomly assigned to receive placebo or 20 mg/day tamoxifen 
for 5 years (Fisher et al. 1998). Gail's algorithm, based on a multivariate logistic regression 
model using combinations of risk factors, was used to estimate the risk of occurrence of 
breast cancer over time.  
Tamoxifen reduced the risk of invasive breast cancer by 49%, with cumulative incidence 
through 69 months of follow-up of 43.4 versus 22.0 per 1000 women in the placebo and 
tamoxifen groups, respectively. The decreased risk occurred in women aged 49 years or 
younger (44%), 50–59 years (51%), and 60 years or older (55%); risk was also reduced in 
women with a history of lobular carcinoma in situ (56%) or atypical hyperplasia (86%) and 
in those with any category of predicted 5-year risk. Tamoxifen reduced the risk of 
noninvasive breast cancer by 50% (two-sided P<.002). Tamoxifen reduced the occurrence of 
estrogen receptor-positive tumors by 69%, but no difference in the occurrence of estrogen 
receptor-negative tumors was seen. Tamoxifen administration did not alter the average 
annual rate of ischemic heart disease; however, a reduction in hip, radius (Colles'), and 
spine fractures was observed.  
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2.1 Endometrial cancer 
The rate of endometrial cancer was increased in the tamoxifen group by more than 2.5-fold 
(risk ratio = 2.53; 95% confidence interval = 1.35–4.97); this increased risk occurred 
predominantly in women aged 50 years or older. All endometrial cancers in the tamoxifen 
group were stage I (localized disease); no endometrial cancer deaths have occurred in this 
group. No liver cancers or increase in colon, rectal, ovarian, or other tumors was observed in 
the tamoxifen group. The rates of stroke, pulmonary embolism, and deep-vein thrombosis 
were elevated in the tamoxifen group; these events occurred more frequently in women 
aged 50 years or older. 
 
 
No. of  
events 
Rate per  
1000 women 
  
Type of cancer Placebo Tam Placebo Tam Diff RR‡ 95% CI 
 Invasive 17 53 0.68 2.24 −1.56 3.28 1.87 to 6.03 
 ≤49 y at entry 9 12 0.82 1.16 −0.34 1.42 0.55 to 3.81 
 ≥50 y at entry 8 41 0.58 3.08 −2.50 5.33 2.47 to 13.17 
 In situ cancer 3 1 0.12 0.04 0.08 0.35 0.01 to 4.36 
Table 1. Events and incidence rates of invasive and in situ endometrial cancer in the placebo 
and tamoxifen groups by age at study entry in the BCPT. 
The average annual rate of invasive endometrial cancer per 1000 participants was 2.30 in the 
tamoxifen group and 0.91 in the placebo group. The increased risk was predominantly in 
women 50 years of age or older. The relative risk of endometrial cancer was 4.01 (95% CI 4 
1.70–10.90) in women aged 50 years or older, and increase in incidence after tamoxifen 
administration was observed early in the follow-up period. Through 66 months of follow-
up, the cumulative incidence was 5.4 per 1000 women and 13.0 per 1000 women in the 
placebo and tamoxifen groups, respectively. Fourteen (93%) of the 15 invasive endometrial 
cancers that occurred in the placebo group were International Federation of Gynecology and 
Obstetrics (FIGO) stage I, and one (7%) was FIGO stage IV. All 36 invasive endometrial 
cancers that occurred in the group receiving tamoxifen were FIGO stage I. Four in situ 
endometrial cancers were reported; three of these occurred in the placebo group and one 
in the tamoxifen group. The cumulative incidence of invasive endometrial carcinoma 
along with other side effects in the trial through seven years of follow-up is shown in 
Figure 1. 
Through 66 months of follow-up, the cumulative incidence was 5.4 per 1000 women and 
13.0 per 1000 women in the placebo and tamoxifen groups, respectively. These rates are 
shown in Figure 2. Fourteen (93%) of the 15 invasive endometrial cancers that occurred in 
the placebo group were International Federation of Gynecology and Obstetrics (FIGO) stage 
I, and one (7%) was FIGO stage IV. All 36 invasive endometrial cancers that occurred in the 
group receiving tamoxifen were FIGO stage I. Four in situ endometrial cancers were 
reported; three of these occurred in the placebo group and one in the tamoxifen group.  
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Fig. 1. Comparison of relative risks (with 95% confidence intervals) of benefits and 
undesirable effects of tamoxifen from the initial and updated results of NSABP P-1. (Fisher 
2005). 
 
 
Fig. 2. Cumulative incidence of invasive endometrial carcinoma through seven years of 
follow-up. 
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After 7 years of follow-up, women who received tamoxifen still had a statistically significantly 
increased risk of invasive endometrial cancer (RR = 3.28, 95% CI = 1.87 to 6.03) (Fisher et al. 
2005). Again, the risk was not increased in women aged 49 years or younger (RR = 1.42, 95% 
CI = 0.55 to 3.81), but there was a statistically significant increase in risk in women aged 50 
years or older (RR = 5.33, 95% CI = 2.47 to 13.17). The cumulative rate of invasive endometrial 
cancer through 7 years of follow-up was 4.68 per 1000 women in the placebo group and 15.64 
per 1000 women in the tamoxifen group, respectively (P<.001). Of the 70 cases of endometrial 
cancer (17 in the placebo group and 53 in the tamoxifen group), 67 cases (15 in the placebo 
group and 52 in the tamoxifen group) were International Federation of Gynecology and 
Obstetrics (FIGO) stage I. Of the remaining two cases in the placebo group, one was stage III 
and one was stage IV. The remaining case in the tamoxifen group was stage III. Four cases of 
endometrial cancer in situ were observed: three in the placebo group and one in the tamoxifen 
group. In addition to these cases of endometrial cancer, there were four cases of uterine 
sarcoma, one in the placebo group and three in the tamoxifen group.  
2.2 Gynecologic and vasomotor symptoms 
Vaginal discharge was reported in almost 55% of women on tamoxifen in the NSABP-P1 
trial, and 78% of women on tamoxifen reported bothersome hot flashes during treatment. 
Results from the Italian trial, which included only women who had a hysterectomy, also 
showed a statistically significant increase in vaginal discharge for women taking tamoxifen 
(RR = 3.44; 95% CI, 2.90 to 4.09).17  
3. Raloxifene 
Raloxifene was the first of a benzothiophene series of antiestrogens to be labeled a SERM. 
Raloxifene has the ability to bind to and activate the estrogen receptor while exhibiting 
tissue-specific effects distinct from estradiol (Vogel 2007). As a result, raloxifene was 
specifically developed to maintain beneficial estrogenic activity on bone and lipids and 
antiestrogenic activity on endometrial and breast tissue. In December 1997, the U.S. Food 
and Drug Administration (FDA) labeled raloxifene for the prevention of osteoporosis. These 
agents work by inducing conformational changes in the estrogen receptor resulting in 
differential expression of specific estrogen-regulated genes in different tissues. Activation of 
the estrogen receptor by raloxifene may involve multiple molecular pathways that may 
result in gene expression of ligand-, tissue- and/or gene-specific receptors 
Raloxifene undergoes extensive systemic biotransformation, but it does not appear to be 
metabolized by the cytochrome P450 pathway. Clinically significant interactions are unlikely 
to occur with drugs typically eliminated by this route. Raloxifene has a plasma elimination 
half-life of approximately 27 hours. This prolonged elimination half-life has been attributed to 
the drug's reversible systemic metabolism and significant enterohepatic cycling. 
Raloxifene appears to lack proliferative effects on endometrial tissue. Data from both animal 
and human studies demonstrate that raloxifene has minimal effects on the uterus and causes 
no significant changes in the histologic appearance of the endometrium (Boss et al. 1997). 
Two six-month studies involving a total of 969 postmenopausal women showed that 
endometrial thickness did not differ between women receiving raloxifene (30 to 150 mg per 
day) and those receiving placebo (Delmas et al. 1997). 
In healthy, postmenopausal women raloxifene (200 to 600 mg per day given over eight 
weeks) does not induce endometrial proliferation as measured by endometrial biopsies. By 
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comparison, 77 percent of the women who receive unopposed estrogen (0.625 mg per day of 
conjugated estrogen) have moderate to marked estrogenic proliferation of endometrial 
tissue. Women who received conjugated estrogen were also noted to have a much higher 
incidence of vaginitis than those who received raloxifene or placebo. 
A trial in 136 healthy postmenopausal women compared the stimulatory effects on the 
uterus of raloxifene (150 mg per day) and continuous hormone replacement therapy (0.625 
mg per day of conjugated estrogen with 2.5 mg per day of medroxyprogesterone). After a 
period of 12 months, the women who received estrogen replacement therapy experienced 
significant changes in endometrial thickness and uterine volume. In contrast, the women 
who were treated with raloxifene exhibited no changes in either parameter. Additional 
short-term trials appear to support the view that raloxifene does not produce endometrial 
stimulation. 
3.1 MORE/CORE trials uterine events 
The MORE trial randomized 7,705 postmenopausal women younger than 81 years (mean 
age= 66.5 years) with osteoporosis to raloxifene or placebo (Cummings et al. 1999). The 
primary aim of the MORE study was to test whether 3 years of raloxifene reduced the risk of 
fracture in postmenopausal women with osteoporosis, and the occurrence of breast cancer 
was a secondary end point. Women were excluded if they took estrogens within 6 months of 
randomization and were not permitted to take concomitant estrogen replacement therapy 
with the study drug. With a median follow-up of 40 months, raloxifene reduced the risk of 
invasive breast cancer by 76% in postmenopausal women with osteoporosis, largely 
accounted for by a 90% reduction in ER-positive breast cancer. Raloxifene did not reduce the 
risk of ER-negative breast cancer. There was no apparent decrease in ER-negative cancers. In 
addition, raloxifene decreased the risk of vertebral fractures and decreased low-density 
lipoprotein cholesterol levels. Raloxifene did not increase the risk of endometrial cancer, 
endometrial hyperplasia or vaginal bleeding (Table 2) but was associated with a threefold 
increase in thromboembolic events. More women in the raloxifene group reported increased 
rates of hot flashes, leg cramps, and peripheral edema. 
The Continuing Outcomes Relevant to Evista (CORE) trial was designed to evaluate the 
efficacy of an additional 4 years of raloxifene therapy in preventing invasive breast cancer in 
women who participated in the MORE trial (Martino et al. 2004). CORE was a multicenter, 
double-blind, placebo-controlled clinical trial. The CORE trial was conducted in the subset 
of the MORE women who agreed to participate in what was an extension of the MORE trial, 
with a change in the primary endpoint from vertebral fracture incidence to invasive breast 
cancer. A secondary objective of the CORE trial was to examine the effect of raloxifene (at 60 
mg/day) on the incidence of invasive ER-positive breast cancer. Women who had been 
randomly assigned to receive raloxifene (either 60 or 120 mg/day) in MORE were assigned 
to receive raloxifene (60 mg/day) in CORE (n= 3510), and women who had been assigned to 
receive placebo in MORE continued on placebo in CORE (n=1703). Women in the raloxifene 
group had a 59% reduction in the incidence of all invasive breast cancer compared with 
women in the placebo group and a 66% reduction in the incidence of invasive ER-positive 
breast cancers compared with women in the placebo group. By contrast, the incidence of 
invasive ER-negative breast cancer in women who received raloxifene was not statistically 
significantly different from that in women who received placebo. The overall incidence of 
breast cancer, regardless of invasiveness, was reduced by 50% in the raloxifene group 
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compared with the placebo group. Again, there was no observed increase in the risk of 
endometrial cancer attributable to raloxifene.  
 
 
CORE enrollees, % (No.) 
4 years beginning at visit  
1 of the CORE trial 
8 years beginning at randomization  
in the MORE trial 
Placebo 
group 
Raloxifene 
group† 
P ‡ 
Placebo 
group Raloxifene group§ 
P ‡ Adverse event (N = 1286) (N = 2725) (N = 1286) (N = 2725) 
Vaginal bleedingǁ 0.20 (2) 0.19 (4) >.99 1.36 (14) 1.25 (27) .87 
Endometrial 
hyperplasiaǁ 0.20 (2) 0.05 (1) .24 0.29 (3) 0.37 (8) >.99 
Endometrial cancerǁ 0.30 (3) 0.19 (4) .69 0.39 (4) 0.32 (7) .75 
* CORE = Continuing Outcomes of Relevant to Evista; MORE = Multiple Outcomes of Raloxifene 
Evaluation.  
† Dose of 60 mg of raloxifene per day during the CORE trial.  
‡ Based on two-sided Fisher's exact test.  
§ Doses of 60 mg or 120 mg of raloxifene per day during the MORE trial and 60 mg of raloxifene per day 
during the CORE trial.  
ǁ Includes only women who had an intact uterus at baseline of the MORE trial. For 4 years beginning at 
visit 1 of CORE, n = 1008 and n = 2138 for the placebo and raloxifene groups, respectively. For 8 years 
beginning at randomization in MORE, n = 1026 and n = 2167 for the placebo and raloxifene groups, 
respectively.  
Table 2. Rates of adverse events among the CORE enrollees*. 
3.2 RUTH Trial 
The Raloxifene Use and the Heart (RUTH) trial randomly assigned 10,101 postmenopausal 
women (mean age, 67.5 years) with CHD or multiple risk factors for coronary heart disease 
(CHD) to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years 
(Barrett-Connor et al. 2006). The two primary outcomes were coronary events (i.e., death 
from coronary causes, myocardial infarction, or hospitalization for an acute coronary 
syndrome) and invasive breast cancer. 
As compared with placebo, raloxifene had no significant effect on the risk of primary 
coronary events, and it reduced the risk of invasive breast cancer (40 vs. 70 events; hazard 
ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute risk reduction, 1.2 invasive 
breast cancers per 1000 women treated for one year); the benefit was primarily due to a 
reduced risk of estrogen-receptor–positive invasive breast cancers. There was no significant 
difference in the rates of death from any cause or total stroke according to group 
assignment, but raloxifene was associated with an increased risk of fatal stroke. Raloxifene 
reduced the risk of clinical vertebral fractures. Raloxifene did not significantly affect the risk 
of CHD. There was no significant difference between the treatment groups in the number of 
women with one or more reported adverse events. More women in the raloxifene group 
than in the placebo group permanently discontinued use of the study drug because of an 
adverse event. 
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Four common adverse events (an acute coronary syndrome, anxiety, constipation, and 
osteoporosis) were reported more frequently in the placebo group than in the raloxifene 
group, and seven (arthritis, cholelithiasis, dyspepsia, hot flush, intermittent claudication, 
muscle spasm, and peripheral edema) were reported more frequently in the raloxifene 
group than in the placebo group (P≤0.05). Hot flushes, leg cramps, peripheral edema, and 
gallbladder disease, all special search categories, were more common in women assigned to 
raloxifene than to placebo. The rates of cholecystectomy did not differ significantly between 
the treatment groups (P=0.25). The incidences of endometrial cancer and all cancers other 
than breast cancer did not differ significantly between treatment groups. Few details were 
provided about the endometrial cancers that were observed. 
3.3 STAR Trial 
The Study of Tamoxifen and Raloxifene (STAR Trial) was conducted to compare the relative 
effects and safety of raloxifene and tamoxifen on the risk of developing invasive breast 
cancer and other disease outcomes (Vogel et al. 2006). It was carried out by The National 
Surgical Adjuvant Breast and Bowel Project Study and was a prospective, double-blind, 
randomized clinical trial conducted in nearly 200 clinical centers throughout North America. 
Patients were 19,747 postmenopausal women of mean age 58.5 years who had increased 5-
year breast cancer risk. Women received either oral tamoxifen (20 mg/d) or raloxifene (60 
mg/d) daily over 5 years. Outcome measures included the incidence of invasive breast 
cancer, uterine cancer, noninvasive breast cancer, bone fractures, and thromboembolic 
events.  
At the time of the planned, initial analysis, there were 163 cases of invasive breast cancer in 
women assigned to tamoxifen and 168 in those assigned to raloxifene (incidence, 4.30 per 
1000 vs. 4.41 per 1000; RR = 1.02; 95% confidence interval [CI], 0.82-1.28). There were 36 
cases of uterine cancer with tamoxifen and 23 with raloxifene (RR = 0.62; 95% CI, 0.35-1.08). 
 
 
Fig. 3. Invasive uterine cancer and thromboembolic events in the STAR Trial. 
After a median of 47 months of follow-up, there was a trend toward a decreased incidence 
of uterine cancer in the raloxifene group, but the difference was not statistically significant—
36 cases (tamoxifen) vs. 23 (raloxifene). Annual incidence rates were 2.00 per 1000 
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(tamoxifen) and 1.25 per 1000 women (raloxifene) (RR = 0.62; 95% CI, 0.35-1.08). Cumulative 
incidence rates through 7 years were 14.7 per 1000 (tamoxifen) and 8.1 per 1000 (raloxifene) 
(P = .07,). These events are shown in Figure 3. Only 1 case of uterine cancer occurred among 
women younger than 50 years, in a participant in the tamoxifen group. The majority of 
women who developed uterine cancer (56 [91%]) were diagnosed with stage I disease. Of 
the remaining cases, there was 1 case of stage II disease in each of the treatment groups, 2 
with stage III disease in the raloxifene group, and 1 with stage IV disease in the raloxifene 
group. Two of these cases were mixed Mullerian cell type; both were in the tamoxifen 
group.  
Table 3 shows that while there were no statistically significant differences with respect to 
risk of uterine cancer, there were differences between the treatment groups indicating that 
the effect of raloxifene on the uterus is less than that of tamoxifen. Among those who did 
not have a diagnosis of uterine cancer, there was a statistically significant difference 
between the groups in the incidence of uterine hyperplasia. The rates were 84% less in the 
raloxifene-treated group (14 cases) than in the tamoxifen-treated group (84 cases) (RR, 
0.16; 95% CI, 0.09-0.29). This magnitude of difference between treatment groups was 
evident for hyperplasia both with and without atypia. For the tamoxifen and raloxifene 
groups, respectively, there were 12 cases and 1 case with atypia (RR, 0.08; 95% CI, 0.00-
0.55) and 72 and 13 cases without atypia (RR, 0.18; 95% CI, 0.09-0.32). There also was a 
statistically significant difference between the treatment groups in the number of 
hysterectomies performed during the course of follow-up. Among women who were not 
diagnosed with endometrial cancer, there were 244 hysterectomies performed in those 
assigned to tamoxifen compared with 111 in those assigned to raloxifene (RR, 0.44; 95% 
CI, 0.35-0.56).  
After 81 months of follow-up, the incidence of invasive uterine cancer was significantly 
lower in the raloxifene group (Vogel et al. 2010). The annual average rate per 1,000 was 2.25 
in the tamoxifen group compared with 1.23 in the raloxifene group (RR = 0.55; 95% CI, 0.36–
0.83). In the original report, the difference between treatment groups for the rate of invasive 
uterine cancer was not statistically significant. The average annual incidence rate of uterine 
hyperplasia, the majority of which was hyperplasia without atypia, was 5 times higher in 
the tamoxifen group (4.40 per 1,000) than in the raloxifene group (0.84 per 1,000; RR = 0.19; 
95% CI, 0.12–0.29). The number of hysterectomies performed in the tamoxifen group, 
including those done for benign disease, was more than double that performed in the 
raloxifene group (RR = 0.45; 95% CI, 0.37–0.54).  
 
Disease/uterine 
event 
Events, n Rate per 1,000 
RR* RR (95% CI) 
Tam Ralox Tam Ralox Diff 
Uterine disease 
and hysterectomy 
Invasive Cancer 65 37 2.25 1.23 1.02 0.55 0.36–0.83 
Hyperplasia 126 25 4.40 0.84 3.56 0.19 0.12–0.29 
Without atypia 104 21 3.63 0.70 2.93 0.19 0.11–0.31 
With atypia 22 4 0.77 0.13 0.64 0.17 0.04–0.51 
Hysterectomy 
during follow-up 
349 162 12.08 5.41 6.67 0.45 0.37–0.54 
Table 3. Uterine Events in the Study of Tamoxifen and Raloxifene (STAR Trial). 
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Previous studies had shown that raloxifene does not increase the risk of uterine 
malignancy when compared with placebo. In the STAR trial, only 59 invasive uterine 
cancers were diagnosed in both study groups during more than 76,000 woman-years of 
follow-up. As noted above, approximately 25% fewer cases of uterine cancer were 
diagnosed in the raloxifene than in the tamoxifen group. Although uterine cancer of the 
mixed Mullerian type occurred in only 2 cases in the tamoxifen group of the STAR trial, 
there have been isolated case reports of this tumor associated with raloxifene. The rates of 
uterine cancer were 2.00 per 1000 (tamoxifen) and 1.25 per 1000 (raloxifene), but this 
difference did not reach statistical significance. Endometrial hyperplasia, however, a risk 
factor for endometrial cancer, was far more common in the tamoxifen-treated group than 
in the raloxifene group (RR, 0.16; 95% CI, 0.09-0.29). The number of participants 
undergoing a hysterectomy for non–cancer-related reasons was significantly reduced 56% 
in the raloxifene group. It is important to note that the difference between the treatment 
groups in non–cancer-related hysterectomies has likely caused an underestimate of the 
true magnitude of endometrial cancer risk associated with tamoxifen and an 
underestimate of the true magnitude of difference between the two treatment groups for 
this end point.  
These data demonstrate that raloxifene is nearly as effective as tamoxifen in reducing the 
risk of invasive breast cancer and has a lower risk of thromboembolic events and cataracts 
but a non-statistically significant higher risk of noninvasive breast cancer. 
3.3.1 Summary for uterine cancer, uterine hyperplasia, and hysterectomy for 
raloxifene and tamoxifen in the STAR Trial 
In the STAR Trial, there was a trend toward a decreased incidence of uterine cancer in the 
raloxifene group, but the difference was not statistically significant—36 cases (tamoxifen) 
vs. 23 (raloxifene). Annual incidence rates were 2.00 per 1000 (tamoxifen) and 1.25 per 
1000 women (raloxifene) (RR, 0.62; 95% CI, 0.35-1.08). Cumulative incidence rates through 
7 years were 14.7 per 1000 (tamoxifen) and 8.1 per 1000 (raloxifene) (P = 0.07,). Only 1 case 
of uterine cancer occurred among women younger than 50 years, in a participant in the 
tamoxifen group. At the time of analysis, clinicopathological stage was unknown for 3 
cases (1 in the tamoxifen group, 2 in the raloxifene group). The majority of the others who 
developed uterine cancer (56 [91%]) were diagnosed with stage I disease. Of the 
remaining cases, there was 1 case of stage II disease in each of the treatment groups, 2 
with stage III disease in the raloxifene group, and 1 with stage IV disease in the raloxifene 
group. As noted, two of these cases were mixed Mullerian cell type; both were in the 
tamoxifen group.  
While there were no significant differences with respect to risk of uterine cancer in the STAR 
trial, there were differences between the treatment groups indicating that the effect of 
raloxifene on the uterus is less than that of tamoxifen. Among those who did not have a 
diagnosis of uterine cancer, there was a statistically significant difference between the 
groups in the incidence of uterine hyperplasia. The rates were 84% less in the raloxifene-
treated group (14 cases) than in the tamoxifen-treated group (84 cases). This magnitude of 
difference between treatment groups was evident for hyperplasia both with and without 
atypia. For the tamoxifen and raloxifene groups, respectively, there were 12 cases and 1 case 
with atypia (RR, 0.08; 95% CI, 0.00-0.55) and 72 and 13 cases without atypia (RR, 0.18; 95% 
CI, 0.09-0.32). There also was a statistically significant difference between the treatment 
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groups in the number of hysterectomies performed during the course of follow-up. Among 
women who were not diagnosed with endometrial cancer, there were 244 hysterectomies 
performed in those assigned to tamoxifen compared with 111 in those assigned to raloxifene 
(RR, 0.44; 95% CI, 0.35-0.56).  
3.3.2 STAR quality of life  
No significant differences existed between the tamoxifen and raloxifene groups in patient-
reported outcomes for physical health, mental health, and depression, although the 
tamoxifen group reported better sexual function (Land et al. 2006). Although mean 
symptom severity was low among these postmenopausal women, those in the tamoxifen 
group reported more gynecological problems, vasomotor symptoms, leg cramps, and 
bladder control problems, whereas women in the raloxifene group reported more 
musculoskeletal problems, dyspareunia, and weight gain.  
3.4 Raloxifene summary 
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and 
Drug Administration (FDA)–approved agent for reducing breast cancer risk but did not 
gain wide acceptance for prevention, largely because it increased the risk of endometrial 
cancer and thromboembolic events. The FDA approved the SERM raloxifene for breast 
cancer risk reduction following its demonstrated effectiveness in preventing invasive breast 
cancer in the Study of Tamoxifen and Raloxifene (STAR). Raloxifene caused less toxicity 
(versus tamoxifen), including reduced thromboembolic events and endometrial cancer. The 
risk ratio (RR; raloxifene:tamoxifen) for invasive breast cancer was 1.24 (95% confidence 
interval [CI], 1.05–1.47) and for noninvasive disease, 1.22 (95% CI, 0.95–1.59). Compared 
with initial results, the RRs widened for invasive and narrowed for noninvasive breast 
cancer.  
With follow-up extended to 81 months in the STAR Trial, toxicity relative risks 
(raloxifene:tamoxifen) were 0.55 (95% CI, 0.36–0.83; P = 0.003) for endometrial cancer (this 
difference was not significant in the initial results), 0.19 (95% CI, 0.12–0.29) for uterine 
hyperplasia, and 0.75 (95% CI, 0.60–0.93) for thromboembolic events. There were no 
significant mortality differences. Long-term raloxifene retained 76% of the effectiveness of 
tamoxifen in preventing invasive disease and grew closer over time to tamoxifen in 
preventing noninvasive disease, with far less toxicity (e.g., highly significantly less 
endometrial cancer). These results have important public health implications and clarify that 
both raloxifene and tamoxifen are good preventive choices for postmenopausal women with 
elevated risk for breast cancer. 
Invasive uterine cancer and uterine hyperplasia are well-established toxicities associated 
with tamoxifen treatment. When compared with tamoxifen, raloxifene does not have such a 
profile. The incidence of invasive uterine cancer is significantly lower in the raloxifene 
group (P = 0.003). The annual average rate per 1,000 was 2.25 in the tamoxifen group 
compared with 1.23 in the raloxifene group (RR = 0.55; 95% CI, 0.36–0.83). In the original 
report of the STAR trial (Vogel et al. 2006), the difference between treatment groups for the 
rate of invasive uterine cancer was not statistically significant. The average annual incidence 
rate of uterine hyperplasia, the majority of which was hyperplasia without atypia, was 5 
times higher in the tamoxifen group (4.40 per 1,000) than in the raloxifene group (0.84 per 
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1,000; RR = 0.19; 95% CI, 0.12–0.29). The number of hysterectomies performed in the 
tamoxifen group (349), including those done for benign disease, was more than double that 
performed in the raloxifene group (162; RR = 0.45; 95% CI, 0.37–0.54).  
4. Lasofoxifene 
Lasofoxifene is a nonsteroidal selective estrogen-receptor modulator that decreases bone 
resorption, bone loss, and low-density- lipoprotein (LDL) cholesterol in postmenopausal 
women. It is a potent third-generation SERM that was developed because of its potentially 
attractive pharmacological profile as an agent for risk reduction of fractures, breast cancer, 
and heart disease in postmenopausal women at increased risk of osteoporotic fractures. 
Preclinical laboratory evidence showed that lasofoxifene reduced bone loss and cholesterol, 
prevented experimental breast cancers, and did not cause endometrial hyperplasia 
(Cummings et al. 2010). Early clinical studies confirmed its potency relative to raloxifene in 
reducing bone loss and serum cholesterol, whereas neither agent increased the risk for 
endometrial hyperplasia.  
As we have seen, currently available selective estrogen receptor modulators reduce the risk 
of breast cancer, but they are not widely used. In the Postmenopausal Evaluation and Risk-
Reduction with Lasofoxifene (PEARL) trial, lasofoxifene reduced the risk of estrogen 
receptor–positive breast cancer, non-vertebral and vertebral fractures, coronary artery 
disease, and stroke. 
The effects on total breast cancer (invasive and ductal carcinoma in situ, ER- positive and 
estrogen receptor–negative) and ER- positive invasive breast cancer were also assessed. 
Postmenopausal women (n = 8556) aged 59–80 years with low bone density and normal 
mammograms were randomly assigned to two doses of lasofoxifene (0.25 and 0.5 mg) or 
placebo. The primary endpoints of the PEARL trial were incidence of ER+ breast cancer 
and non-vertebral fractures at 5 years (LaCroix et al. 2010). A nested case–control study of 
49 incident breast cancer case patients and 156 unaffected control subjects from the 
PEARL trial was performed to evaluate treatment effects on risk of total and ER- positive 
invasive breast cancer by baseline serum estradiol and sex hormone–binding globulin 
levels. Breast cancer was confirmed in 49 women. Compared with placebo, 0.5 mg of 
lasofoxifene significantly reduced the risk of total breast cancer by 79% (hazard ratio = 
0.21; 95% confidence interval [CI] = 0.08 to 0.55) and ER+ invasive breast cancer by 83% 
(hazard ratio = 0.17; 95% CI = 0.05 to 0.57). The effects of 0.5 mg of lasofoxifene on total 
breast cancer were similar regardless of Gail breast cancer risk score, whereas the effects 
were markedly stronger for women with baseline estradiol levels greater than the median 
(odds ratio = 0.11; 95% CI = 0.02 to 0.51) vs. those with levels less than the median (odds 
ratio = 0.78; 95% CI = 0.16 to 3.79).  
These data confirm that a 0.5-mg dose of lasofoxifene appears to reduce the risks of both 
total and ER-positive invasive breast cancer in postmenopausal women with osteoporosis.  
Lasofoxifene at a dose of 0.5 mg per day, as compared with placebo, is associated with 
reduced risks of vertebral fracture, non-vertebral fracture, ER-positive breast cancer, 
coronary heart disease events, and stroke. Lasofoxifene at a dose of 0.25 mg per day, as 
compared with placebo, is associated with reduced risks of vertebral fracture and stroke. 
Both the lower and higher doses, as compared with placebo, were associated with an 
increase in venous thromboembolic events, respectively. Endometrial cancer occurred in 
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three women in the placebo group, two women in the lower-dose lasofoxifene group, and 
two women in the higher-dose lasofoxifene group. Endometrial cancers were diagnosed in 
two women in each lasofoxifene group and three women in the placebo group. Endometrial 
hyperplasia was confirmed in two women in the higher-dose lasofoxifene group, three 
women in the lower-dose lasofoxifene group, and no women in the placebo group. This 
SERM may represent a much safer option than either tamoxifen or raloxifene for the 
prevention of both osteoporosis and invasive breast cancer. 
A prospective study established the gynecological effects of 5 years of treatment with 
lasofoxifene versus placebo in postmenopausal osteoporotic women (Goldstein et al. 
2011). The results are shown in Table 4. A total of 8,556 women aged 59 to 80 years with 
femoral neck or spine bone mineral density T scores of -2.5 or lower were randomly 
assigned to receive either lasofoxifene 0.25 mg/day, or lasofoxifene 0.5 mg/day, or 
placebo, for 5 years.  
 
 
Lasofoxifene  
0.25 mg/day 
Lasofoxifene 
0.50 mg/day 
Placebo 
Endometrial cancer 
(number of cases) 
2 2 3 
Uterine hyperplasia 
(number of cases) 
3 2 0 
Vaginal bleeding 
(percent) 
2.2%* 2.6%* 1.3% 
Surgery for 
prolapsed or 
incontinence 
(percent) 
1.9%* 1.6% 1.2% 
Endometrial polyps 
(percent) 
8.8%* 5.5* 3.3% 
*Statistically significant difference from placebo. 
Table 4. Rates of gynecological events among postmenopausal women taking lasofoxifene.  
Endometrial cancer was confirmed for two women in each lasofoxifene group and for three 
women in the placebo group. Endometrial hyperplasia and vaginal bleeding occurred in 
more women treated with either 0.25 mg/day or 0.5 mg/day lasofoxifene than in women 
treated with placebo. Lasofoxifene treatment resulted in a small increase in endometrial 
thickness versus placebo. Similar numbers of women required surgery for pelvic organ 
prolapse or urinary incontinence in the placebo and 0.5 mg/day lasofoxifene groups. These 
findings indicate that 5 years of lasofoxifene treatment result in benign endometrial changes 
that do not increase the risk for endometrial cancer or hyperplasia in postmenopausal 
women. 
5. Population risks and benefits of SERM therapy 
The risks associated with tamoxifen therapy are shown in Table 5. Using the rates shown in 
the table, we can calculate that among the more than 65 million women aged 35–79 years 
without reported breast cancer in the United States in 2000, 10 million women (Freedman et 
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al. 2003) would have been eligible for tamoxifen chemoprevention. The percentage of U.S. 
women who would be eligible varied dramatically by race, with 18.7% (95% CI = 17.8% to 
19.7%) of white women, 5.7% (95% CI = 4.3% to 7.5%) of black women, and 2.9% (95% CI = 
2.1% to 3.9%) of Hispanic women being eligible. Of the 50 million white U.S. women aged 
35–79 years, more than 2.4 million (would have a positive benefit/risk index for tamoxifen 
chemoprevention. Of the 7 million black U.S. women aged 35–79 years, only 42,000 would 
have a positive benefit/risk index. Among white women, more than 28,000 breast cancers 
would be prevented or deferred if those women who have a positive net benefit index took 
tamoxifen over the next 5 years.: A substantial percentage of U.S. women are eligible for 
chemoprevention according to FDA criteria, and a percentage of them would have an 
estimated net benefit. Nevertheless, this latter percentage corresponds to more than two 
million women. 
Revised estimates show that of the more than 9 million white U.S. women in 2010 who 
would be eligible for tamoxifen chemoprevention, about one-third would derive a net 
benefit from taking the drug on the basis of their age and breast cancer risk factors 
(Freedman et al. 2011). Among the white women who would benefit from tamoxifen, 
approximately more than 58,000 invasive breast cancers will develop over the next 5 
years. If all 2 431 911 women in the US with an estimated net benefit/risk index took 
tamoxifen over the next 5 years, and if the risk reduction of 49% applies, then 28 492 of 
these breast cancers would be prevented, or deferred, which would be a substantial 
achievement.  
 
Type of event 
Age groups for white women 
(years) 
Age groups for black women 
(years) 
35-39 40-49 50-59 60-69 70-79 35-39 40-49 50-59 60-69 70-79 
Life-threatening 
events  
          
Hip fracture  1 1 22 52 151 1 1 12 20 57 
Endometrial cancer  −2 −16 −120 −206 −223 −1 −6 −52 −126 −119 
(without uterus) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0) 
Stroke  −2 −13 −32 −91 −196 −8 −36 −90 −200 −228 
Pulmonary 
embolism  
−7 −15 −49 −85 −177 −20 −46 −145 −189 −273 
Severe events            
Deep vein 
thrombosis  
−13 −15 −16 −28 −44 −37 −45 −48 −63 −69 
Other events            
Colles' fracture  11 11 19 25 25 9 9 10 10 9 
Spine fracture  2 2 23 46 90 1 1 13 17 62 
Cataracts  −35 −35 −101 −269 −384 −35 −35 −100 −264 −377 
Table 5. Numbers of non-breast cancer events prevented (positive number) or caused 
(negative number) in 5 years among 10,000 women treated with tamoxifen (Gail et al. 1999). 
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For non-Hispanic white women age 50 years or older with a uterus, raloxifene displays a 
better benefit/risk profile than tamoxifen overall (Freedman et al. 2011). For tamoxifen, 
women age 50 to 59 years with a 5-year risk of invasive breast cancer of 4.5% to 6.5% 
showed moderate evidence of net positive benefit, and women with risk of 7.0% or higher 
showed strong evidence. For women age 50 to 59 years with a 5-year risk of invasive breast 
cancer less than 4.0%, the risks outweighed the benefits. The risks outweighed the benefits 
for women age 60 years or older, regardless of IBC risk. In contrast, for raloxifene, there was 
strong evidence that benefits outweighed risks, compared with placebo, for women age 50 
to 59 years with a 5-year breast cancer risk of 3.5% or higher and for women age 60 to 69 
years with an risk of 6.5% risk or higher. There was moderate evidence of a net benefit for 
women age 50 to 59 years with a 5-year risk of 2.0% to 3.0%, women age 60 to 69 years with 
a 5-year risk of 3.0% to 6.0%, and women age 70 to 79 years with a 5-year IBC risk of 4.0% or 
higher. For postmenopausal black and Hispanic women with a uterus, raloxifene also 
displayed a better benefit/risk profile than tamoxifen and in a similar pattern to that for 
whites. Net benefit indices tended to be larger in Hispanic women and smaller in black 
women than in white women, however.  
6. American Society of Clinical Oncology (ASCO ) recommendations for 
breast cancer risk reduction  
In premenopausal women, tamoxifen for 5 years reduces the risk of breast cancer for at 
least 10 years, particularly estrogen receptor (ER) –positive invasive tumors. Women ≤ 50 
years of age experience fewer serious side effects. Vascular and vasomotor events do not 
persist post-treatment across all ages. In postmenopausal women, raloxifene and 
tamoxifen reduce the risk of ER-positive invasive BC with equal efficacy. Raloxifene is 
associated with a lower risk of thromboembolic disease, benign and malignant uterine 
conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists 
establishing whether a reduction in risk of breast cancer from either agent translates into 
reduced BC mortality. 
6.1 2009 Recommendation for the Use of tamoxifen to reduce the risk of developing 
breast cancer 
Five years of tamoxifen (20 mg/d) may be offered to women at increased risk of breast 
cancer to reduce their risk of estrogen receptor (ER) –positive invasive breast cancers for 
up to 10 years (Visvanathan et al. 2009). Eligible women include those with a 5-year 
projected breast cancer risk ≥ 1.66% (according to the National Cancer Institute [NCI] 
Breast Cancer Risk Assessment Tool based on the Gail model23 —available at 
http://www.cancer.gov/bcrisktool) or women with LCIS. The benefit of taking tamoxifen 
for more than 5 years is unknown. The greatest clinical benefit and the fewest side effects 
were derived from the use of tamoxifen in younger (premenopausal) women 35 to 50 
years of age who are unlikely to experience thromboembolic sequelae or uterine cancer, 
women without a uterus, and women at high risk of breast cancer (Newman and Vogel 
2007). Vascular and vasomotor side effects were observed to decline post-treatment across 
all ages. Tamoxifen is not recommended in women with a prior history of deep vein 
thrombosis (DVT), pulmonary embolus (PE), stroke, or transient ischemic attack. Combined 
use of tamoxifen for breast cancer prevention and hormone therapy (HT) is currently not 
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recommended. Follow-up should include a baseline gynecologic examination before 
initiation of treatment and annually thereafter, with a timely work-up for abnormal vaginal 
bleeding. The risks and benefits of tamoxifen should be given careful consideration during 
the decision-making process. There has been no mortality differences observed in the 
tamoxifen prevention trials so far, most likely because these trials were not powered to 
detect such outcomes. Nevertheless, a reduction in breast cancer incidence is considered to 
be an important health outcome in and of itself.  
6.2 ASCO 2009 recommendation for the use of raloxifene to reduce the risk of 
developing breast cancer 
For postmenopausal women at increased risk for breast cancer, raloxifene (60 mg/d) for 5 
years may be offered as another option to reduce the risk of ER-positive invasive breast 
cancer. Raloxifene has been shown to be equally efficacious to tamoxifen in reducing breast 
cancer risk in postmenopausal women. However, raloxifene was not as effective in reducing 
the incidence of noninvasive breast cancer compared with tamoxifen, although the 
association was not statistically significant. In the STAR trial, raloxifene was associated with 
a more favorable side-effect profile compared with tamoxifen, including a statistically 
significant lower risk of thromboembolic disease, benign uterine complaints, and cataracts 
as compared with tamoxifen. Raloxifene, like tamoxifen, is not known to have an effect on 
overall or breast cancer–specific mortality in women at increased risk of breast cancer. 
However, the risk reduction trials were not powered to detect a reduction in breast cancer 
incidence rather than mortality, as it was felt to be an important end point in and of itself. 
Raloxifene may be used for longer than 5 years in women with osteoporosis in whom breast 
cancer risk reduction is an additional potential benefit. Raloxifene is not recommended in 
premenopausal women or in women with a prior history of DVT, PE, stroke, or transient 
ischemic attack. In postmenopausal women, the risks and benefits of both tamoxifen and 
raloxifene, including risks of noninvasive breast cancer, adverse events, and impact on 
quality of life, should be discussed in detail with women before coming to a decision about 
risk reduction strategies.  
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